HRP20110094T8 - Solid preparation comprising alogliptin and pioglitazone - Google Patents

Solid preparation comprising alogliptin and pioglitazone

Info

Publication number: HRP20110094T8
Authority: HR; Croatia
Prior art keywords: pioglitazone; alogliptin; solid preparation; sugar; excipient
Prior art date: 2007-02-01

Application number

HR20110094T

Other languages

English (en)

Croatian (hr)

Inventor

Nakamura Kenji

Kiyoshima Kenichiro

Nomura Junya

Original Assignee

Takeda Pharmaceutical Company Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-01

Filing date

2008-01-30

Publication date

2011-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39240362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110094(T8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-01-30 Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited

2011-03-31 Publication of HRP20110094T1 publication Critical patent/HRP20110094T1/hr

2011-07-31 Publication of HRP20110094T8 publication Critical patent/HRP20110094T8/xx

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

HR20110094T 2007-02-01 2008-01-30 Solid preparation comprising alogliptin and pioglitazone HRP20110094T8 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2007023594		2007-02-01
PCT/JP2008/051900 WO2008093882A1 (en)	2007-02-01	2008-01-30	Solid preparation comprising alogliptin and pioglitazone

Publications (2)

Publication Number	Publication Date
HRP20110094T1 HRP20110094T1 (hr)	2011-03-31
HRP20110094T8 true HRP20110094T8 (en)	2011-07-31

Family

ID=39240362

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20110094T HRP20110094T8 (en)	2007-02-01	2008-01-30	Solid preparation comprising alogliptin and pioglitazone

Country Status (38)

Country	Link
US (1)	US8637079B2 (de)
EP (1)	EP2107905B1 (de)
JP (1)	JP5284968B2 (de)
KR (1)	KR101486091B1 (de)
CN (1)	CN101646420B (de)
AR (1)	AR065097A1 (de)
AT (1)	ATE488227T1 (de)
AU (1)	AU2008211981B2 (de)
BR (1)	BRPI0807453B8 (de)
CA (1)	CA2677201C (de)
CL (1)	CL2008000279A1 (de)
CR (1)	CR10992A (de)
CY (1)	CY1111264T1 (de)
DE (1)	DE602008003522D1 (de)
DK (1)	DK2107905T3 (de)
DO (1)	DOP2009000195A (de)
EA (1)	EA015180B1 (de)
EC (1)	ECSP099608A (de)
ES (1)	ES2354397T3 (de)
GE (1)	GEP20125410B (de)
HR (1)	HRP20110094T8 (de)
IL (1)	IL200108A (de)
JO (1)	JO2650B1 (de)
MA (1)	MA31169B1 (de)
ME (1)	ME01239B (de)
MX (1)	MX2009008100A (de)
MY (1)	MY147596A (de)
NZ (1)	NZ579008A (de)
PE (1)	PE20081663A1 (de)
PL (1)	PL2107905T3 (de)
PT (1)	PT2107905E (de)
RS (1)	RS51592B (de)
SI (1)	SI2107905T1 (de)
TN (1)	TN2009000317A1 (de)
TW (2)	TWI453041B (de)
UA (1)	UA95828C2 (de)
WO (1)	WO2008093882A1 (de)
ZA (1)	ZA200905621B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP2540725A1 (de)	2006-05-04	2013-01-02	Boehringer Ingelheim International GmbH	Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
EP1852108A1 (de)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Zusammensetzungen von DPP-IV-Inhibitoren
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EA020870B1 (ru) *	2007-07-19	2015-02-27	Такеда Фармасьютикал Компани Лимитед	Твердый препарат, включающий алоглиптин и гидрохлорид метформина
CL2008002427A1 (es)	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
NZ604091A (en)	2008-08-15	2014-08-29	Boehringer Ingelheim Int	Purin derivatives for use in the treatment of fab-related diseases
CN102149407A (zh)	2008-09-10	2011-08-10	贝林格尔.英格海姆国际有限公司	治疗糖尿病和相关病症的组合疗法
UY32126A (es)	2008-09-25	2010-04-30	Takeda Pharmaceutical	Composición farmacéutica sólida
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh)	2008-12-23	2011-11-23	贝林格尔.英格海姆国际有限公司	有机化合物的盐形式
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es)	2009-01-29	2011-03-16	Boehringer Ingelheim Int	Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
AU2010212823B2 (en)	2009-02-13	2016-01-28	Boehringer Ingelheim International Gmbh	Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
JP5685550B2 (ja)	2009-02-13	2015-03-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
KR20240090632A (ko) *	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP2547339A1 (de)	2010-03-18	2013-01-23	Boehringer Ingelheim International GmbH	Kombination eines gpr119-agonisten und des dpp-iv-hemmers linagliptin zur verwendung bei der behandlung von diabetes und zugehöriger erkrankungen
CN102946875A (zh)	2010-05-05	2013-02-27	贝林格尔.英格海姆国际有限公司	组合疗法
AR082091A1 (es) *	2010-05-05	2012-11-14	Boehringer Ingelheim Int	Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion
WO2011161161A1 (en)	2010-06-24	2011-12-29	Boehringer Ingelheim International Gmbh	Diabetes therapy
CN101912363A (zh) *	2010-07-29	2010-12-15	蔡海德	溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AR085689A1 (es)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US8883800B2 (en)	2011-07-15	2014-11-11	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
JP6218811B2 (ja)	2012-05-14	2017-10-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103877054B (zh) *	2012-12-21	2016-05-25	北大方正集团有限公司	一种苯甲酸阿格列汀片剂及其制备方法
CN103156819A (zh) *	2013-03-29	2013-06-19	山东罗欣药业股份有限公司	苯甲酸阿格列汀组合物片剂及其制备方法
EP3110449B1 (de)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Medizinische verwendung eines dpp-4-inhibitors
JP6027710B1 (ja) *	2014-12-25	2016-11-16	田辺三菱製薬株式会社	糖尿病治療用固形製剤
US10548848B2 (en) *	2015-06-17	2020-02-04	Hexal Ag	Alogliptin formulation
RU2697836C2 (ru)	2015-06-26	2019-08-21	Кореа Юнайтед Фарм. Инк.	Комбинированный препарат мозаприда и рабепразола
CN105030719B (zh) *	2015-08-20	2018-07-20	杭州成邦医药科技有限公司	一种含有阿格列汀和吡格列酮的组合物
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合
KR102485766B1 (ko)	2019-12-11	2023-01-09	한국유나이티드제약 주식회사	생체이용률이 향상된 피오글리타존 함유 약학조성물
CN113925838B (zh) *	2021-11-11	2022-11-11	乐普制药科技有限公司	一种依帕司他与西格列汀或其可药用盐的复方缓释片及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR240698A1 (es) *	1985-01-19	1990-09-28	Takeda Chemical Industries Ltd	Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DK0559702T3 (da)	1990-11-27	1995-05-15	Byk Gulden Lomberg Chem Fab	Urapidil-slow-release-præparat
TWI238064B (en) *	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
JP2931811B2 (ja)	1997-06-03	1999-08-09	ユニコロイド株式会社	徐放性カプセル
US6030641A (en) *	1997-06-03	2000-02-29	Uni Colloid Kabushiki Kaisha	Sustained release capsule and method for preparing the same
DE19725911A1 (de)	1997-06-13	1998-12-17	Roland Prof Dr Bodmeier	Zusammensetzungen, die die Wirkstofffreisetzung verzögern
AU8532798A (en)	1997-06-13	1998-12-30	Roland Bodmeier	Compounds which delay the release of active substances
WO2000016776A1 (fr)	1998-09-18	2000-03-30	Takeda Chemical Industries, Ltd.	Preparations a administrer par voie buccale a liberation lente
JP2000154137A (ja)	1998-09-18	2000-06-06	Takeda Chem Ind Ltd	徐放性経口製剤
EP1849475A1 (de) *	1999-06-21	2007-10-31	Eli Lilly & Company	Synergistische Verwendung von Thiazolidindionen mit glucagonartigem Peptid-1 und Agonisten davon zur Behandlung von nicht insulinabhängigen Diabetes
MY125516A (en)	1999-11-16	2006-08-30	Smithkline Beecham Plc	Novel composition based on thiazolidinedione and metformin and use
EP1743655B1 (de)	2000-01-21	2014-06-25	Novartis AG	Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
US6395767B2 (en)	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US7078397B2 (en) *	2000-06-19	2006-07-18	Smithkline Beecham Corporation	Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB0014969D0 (en) *	2000-06-19	2000-08-09	Smithkline Beecham Plc	Novel method of treatment
US6573287B2 (en)	2001-04-12	2003-06-03	Bristo-Myers Squibb Company	2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
AR034517A1 (es) *	2001-06-21	2004-02-25	Astrazeneca Ab	Formulacion farmaceutica
UA74912C2 (en) *	2001-07-06	2006-02-15	Merck & Co Inc	Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US8329217B2 (en) *	2001-11-06	2012-12-11	Osmotica Kereskedelmi Es Szolgaltato Kft	Dual controlled release dosage form
EP1552832A1 (de) *	2002-07-11	2005-07-13	Takeda Pharmaceutical Company Limited	Verfahren zur herstellung einer beschichteten zubereitung
IN192749B (de)	2002-11-15	2004-05-15	Ranbaxy Lab Ltd
JP4567340B2 (ja) *	2003-01-29	2010-10-20	武田薬品工業株式会社	被覆製剤の製造方法
EP1588708A4 (de) *	2003-01-29	2006-03-01	Takeda Pharmaceutical	Verfahren zur herstellung einer beschichteten zubereitung
CA2540225C (en) *	2003-10-31	2012-03-06	Takeda Pharmaceutical Company Limited	Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester
JP4361461B2 (ja)	2003-10-31	2009-11-11	武田薬品工業株式会社	固形製剤
RU2766487C2 (ru)	2004-01-20	2022-03-15	Новартис Аг	Композиция и способ прямого прессования
UA85871C2 (uk) *	2004-03-15	2009-03-10	Такеда Фармасьютікал Компані Лімітед	Інгібітори дипептидилпептидази
AU2005299808B2 (en)	2004-10-25	2009-08-20	Novartis Ag	Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin
GT200600218A (es)	2005-06-10	2007-03-28		Formulación y proceso de compresión directa
PT1931350E (pt)	2005-09-14	2014-02-12	Takeda Pharmaceutical	Administração de inibidores de dipeptidil peptidase
TW200745079A (en)	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
AR058605A1 (es)	2005-12-22	2008-02-13	Takeda Pharmaceutical	Preparacion solida
JP5094416B2 (ja) *	2005-12-28	2012-12-12	武田薬品工業株式会社	糖尿病治療剤

2008
- 2008-01-30 TW TW097103417A patent/TWI453041B/zh active
- 2008-01-30 RS RS20110080A patent/RS51592B/sr unknown
- 2008-01-30 ME MEP-2011-167A patent/ME01239B/me unknown
- 2008-01-30 MX MX2009008100A patent/MX2009008100A/es active IP Right Grant
- 2008-01-30 DK DK08704473.1T patent/DK2107905T3/da active
- 2008-01-30 UA UAA200909031A patent/UA95828C2/ru unknown
- 2008-01-30 JP JP2009532078A patent/JP5284968B2/ja active Active
- 2008-01-30 NZ NZ579008A patent/NZ579008A/en unknown
- 2008-01-30 MY MYPI20093188A patent/MY147596A/en unknown
- 2008-01-30 PL PL08704473T patent/PL2107905T3/pl unknown
- 2008-01-30 WO PCT/JP2008/051900 patent/WO2008093882A1/en not_active Ceased
- 2008-01-30 GE GEAP200811445A patent/GEP20125410B/en unknown
- 2008-01-30 US US12/449,255 patent/US8637079B2/en active Active
- 2008-01-30 BR BRPI0807453A patent/BRPI0807453B8/pt active IP Right Grant
- 2008-01-30 PE PE2008000222A patent/PE20081663A1/es active IP Right Grant
- 2008-01-30 DE DE602008003522T patent/DE602008003522D1/de active Active
- 2008-01-30 CA CA2677201A patent/CA2677201C/en active Active
- 2008-01-30 PT PT08704473T patent/PT2107905E/pt unknown
- 2008-01-30 ES ES08704473T patent/ES2354397T3/es active Active
- 2008-01-30 SI SI200830149T patent/SI2107905T1/sl unknown
- 2008-01-30 CL CL200800279A patent/CL2008000279A1/es unknown
- 2008-01-30 ZA ZA200905621A patent/ZA200905621B/xx unknown
- 2008-01-30 AR ARP080100381A patent/AR065097A1/es not_active Application Discontinuation
- 2008-01-30 CN CN2008800103744A patent/CN101646420B/zh active Active
- 2008-01-30 AT AT08704473T patent/ATE488227T1/de active
- 2008-01-30 HR HR20110094T patent/HRP20110094T8/xx unknown
- 2008-01-30 EA EA200970726A patent/EA015180B1/ru active Protection Beyond IP Right Term
- 2008-01-30 TW TW102128229A patent/TW201350143A/zh unknown
- 2008-01-30 EP EP08704473A patent/EP2107905B1/de active Active
- 2008-01-30 KR KR1020097017913A patent/KR101486091B1/ko active Active
- 2008-01-30 AU AU2008211981A patent/AU2008211981B2/en active Active
- 2008-02-02 JO JO200830A patent/JO2650B1/en active
2009
- 2009-07-28 IL IL200108A patent/IL200108A/en active IP Right Grant
- 2009-07-30 TN TNP2009000317A patent/TN2009000317A1/fr unknown
- 2009-07-31 DO DO2009000195A patent/DOP2009000195A/es unknown
- 2009-08-06 MA MA32148A patent/MA31169B1/fr unknown
- 2009-08-24 CR CR10992A patent/CR10992A/es unknown
- 2009-08-31 EC EC2009009608A patent/ECSP099608A/es unknown
2011
- 2011-02-09 CY CY20111100150T patent/CY1111264T1/el unknown

Also Published As

Publication number	Publication date
HRP20110094T1 (hr)	2011-03-31
ZA200905621B (en)	2010-10-27
BRPI0807453B1 (pt)	2021-01-05
EP2107905B1 (de)	2010-11-17
TW200836775A (en)	2008-09-16
DK2107905T3 (da)	2011-01-31
BRPI0807453A2 (pt)	2014-05-20
TN2009000317A1 (en)	2010-12-31
JP2010517937A (ja)	2010-05-27
GEP20125410B (en)	2012-02-27
US8637079B2 (en)	2014-01-28
DE602008003522D1 (de)	2010-12-30
JO2650B1 (en)	2012-06-17
ECSP099608A (es)	2009-09-29
TWI453041B (zh)	2014-09-21
RS51592B (sr)	2011-08-31
CA2677201A1 (en)	2008-08-07
EP2107905A1 (de)	2009-10-14
PT2107905E (pt)	2010-12-17
JP5284968B2 (ja)	2013-09-11
CR10992A (es)	2009-09-16
MX2009008100A (es)	2009-08-07
WO2008093882A1 (en)	2008-08-07
KR101486091B1 (ko)	2015-01-23
KR20090109115A (ko)	2009-10-19
AR065097A1 (es)	2009-05-13
CN101646420A (zh)	2010-02-10
PE20081663A1 (es)	2008-12-25
AU2008211981A1 (en)	2008-08-07
ME01239B (me)	2013-06-20
BRPI0807453B8 (pt)	2021-05-25
US20100092551A1 (en)	2010-04-15
TW201350143A (zh)	2013-12-16
MY147596A (en)	2012-12-31
CA2677201C (en)	2015-11-17
IL200108A (en)	2012-02-29
IL200108A0 (en)	2010-04-15
AU2008211981B2 (en)	2012-09-20
UA95828C2 (ru)	2011-09-12
SI2107905T1 (sl)	2011-03-31
CL2008000279A1 (es)	2008-08-18
MA31169B1 (fr)	2010-02-01
CY1111264T1 (el)	2015-08-05
CN101646420B (zh)	2012-11-07
ES2354397T3 (es)	2011-03-14
DOP2009000195A (es)	2009-08-31
HK1138188A1 (en)	2010-08-20
NZ579008A (en)	2012-02-24
EA200970726A1 (ru)	2010-02-26
EA015180B1 (ru)	2011-06-30
ATE488227T1 (de)	2010-12-15
PL2107905T3 (pl)	2011-04-29

Publication	Publication Date	Title
HRP20110094T8 (en)	2011-07-31	Solid preparation comprising alogliptin and pioglitazone
EA200800727A1 (ru)	2008-08-29	Введение ингибиторов дипептидилпептидазы
MX2007014892A (es)	2008-04-17	Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico .
MA30725B1 (fr)	2009-09-01	Administration d'inhibiteurs de la dipeptidyl peptidase
LTPA2013005I1 (lt)	2013-03-25	Enantiomerų atžvilgiu gryni aminoheteroarilo junginiai, kaip proteinkinazės inhibitoriai
CY2015016I2 (el)	2018-01-10	Αναστολεις της κινασης τυροσινης του bruton
ATE447568T1 (de)	2009-11-15	Neue pyrinderivate
MA31433B1 (fr)	2010-06-01	Inhibiteurs de la p70 s6 kinase
ZA200700084B (en)	2008-02-27	2,4-DI(aminopheyl) pyrimidines AS PKL inhibitors
MA30531B1 (fr)	2009-06-01	Anticorps anti-dll4 et leurs procedes d'utilisation
UY32649A (es)	2010-12-31	"sales de 4-(dimetilamino)butil 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato"
UA102534C2 (xx)	2013-07-25	ТВЕРДА ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДІОКСОЛ-5-ІЛ)-ЦИКЛОПРОПАНКАРБОКСАМІДО)-3-МЕТИЛПІРИДИН-2-ІЛ)БЕНЗОЙНОЇ КИСЛОТИ (ВАРІАНТИ)$ТВЕРДАЯ ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДИОКСОЛ-5-ИЛ)-ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНОЙ КИСЛОТЫ (ВАРИАНТЫ)
EA200702198A1 (ru)	2008-04-28	Фармацевтические составы
DK1725218T3 (da)	2014-09-01	Farmaceutisk sammensætning omfattende pimobendan
EP2046361A4 (de)	2011-06-29	Osteogene verstärkerzusammensetzung
DE602005017719D1 (de)	2009-12-31	Wässrige, flüssige Pulverformulierungen ohne Alkohol
EA201270204A1 (ru)	2012-08-30	Таблетка
ECSP10010576A (es)	2010-12-30	Formulaciones orales e inyectables de compuestos de tetraciclina
ITFI20080016A1 (it)	2009-08-06	Formulazioni farmaceutiche orali contenenti gliclazide.
EP1941880A4 (de)	2010-12-29	Ein pyridoncarbonsäure-derivat enthaltende lotion
NO20065791L (no)	2007-01-30	Asyklovir-formuleringer
DK1948126T3 (da)	2013-03-11	Oral sammensætning indeholdende morin
CY1107277T1 (el)	2012-11-21	Βενζισοξαζολες
EP1850829A4 (de)	2012-12-26	Neue propofolzusammensetzung mit ascorbinsäure oder pharmazeutisch nutzbaren salzen davon
TW200833325A (en)	2008-08-16	Pharmaceutical composition comprising ascorbic acid